CJC-1295 (No DAC) is the synthetic 29-residue C-terminally amidated peptide usually designated modified GRF (1-29): a tetrasubstituted analog of human growth-hormone-releasing hormone, GHRH(1-29), bearing the non-natural residue D-Ala at position 2 together with Gln8, Ala15 and Leu27. It differs from sermorelin, the unmodified GHRH(1-29) amide, at those four positions, and from the separate DAC-bearing conjugate reported under the same research code, which additionally carries a maleimidopropionyl-lysine linker.

Literature on GHRH(1-29) analogs reports agonist activity at the class B G-protein-coupled GHRH receptor (GHRHR), which couples through Gs to adenylyl cyclase and raises cyclic AMP in pituitary somatotroph preparations. Substitution at position 2 is reported to slow cleavage of the peptide by dipeptidyl peptidase-IV in plasma incubations.

Cited in GPCR pharmacology, GHRH-receptor binding and cyclase assays, pituitary somatotroph cell models, peptide-stability work and LC-MS/MS method development for GHRH analogs and their in-vitro metabolites. Supplied as a lyophilized solid; hygroscopic.

Research use only. This material is sold for in-vitro laboratory research and development purposes exclusively. It is not a drug, food, or dietary supplement, has not been evaluated by the FDA, and must not be used in humans or animals.